Madrid, December 12 (EFECOM). – The National Market and Competition Commission (CNMC) has approved the sale, agreed on November 4, of 100% of Aspy, the professional risk division of Atrys, to the Echevarne Group for 145 million euros.
The purchase and sale agreement also provided for a conditional payment of up to 5 million in the event that the buyer transfers the asset to a third party within the year after closing for an amount greater than the agreed amount.
It was also noted that the completion of the operation is subject to compliance with certain conditions precedent, including the aforementioned obtaining of approval from the CNMC, which Atrys notified to the National Securities Market Commission (CNMV) on Friday.
Final completion of operations is expected in the first quarter of 2026.
Atrys also informed CNMV that the divestment of its prevention business will allow it to focus its resources on its key business areas of precision medical diagnosis and treatment; as well as strengthening financial strength and accelerating organic growth. EFECOM
About The Author
